<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The major cause of <z:hpo ids='HP_0011420'>death</z:hpo> and complications in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Cardiovascular complications that are often associated with <z:mp ids='MP_0002055'>diabetes</z:mp> include <z:hpo ids='HP_0001635'>heart failure</z:hpo>, <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> (MI), <z:hpo ids='HP_0004950'>peripheral vascular disease</z:hpo>, and cerebrovascular disease </plain></SENT>
<SENT sid="2" pm="."><plain>More than 60% of <z:hpo ids='HP_0000001'>all</z:hpo> patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> die of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e>, and an even greater percentage have serious complications </plain></SENT>
<SENT sid="3" pm="."><plain>The impact of <z:chebi fb="105" ids="17234">glucose</z:chebi> lowering on cardiovascular complications is a hotly debated issue and recent large clinical trials, the Action in <z:mp ids='MP_0002055'>Diabetes</z:mp> and <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">Vascular Disease</z:e> (ADVANCE), Action to Control Cardiovascular Risk in <z:mp ids='MP_0002055'>Diabetes</z:mp> (ACCORD) and Veterans Affairs <z:mp ids='MP_0002055'>Diabetes</z:mp> Trial (VADT) reported no significant decrease in cardiovascular events with intensive <z:chebi fb="105" ids="17234">glucose</z:chebi> control </plain></SENT>
<SENT sid="4" pm="."><plain>Risk remains high even after correcting <z:mp ids='MP_0002055'>diabetes</z:mp>-associated <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> (high <z:chebi fb="4" ids="17855">triglycerides</z:chebi> and low <z:chebi fb="17" ids="39025">HDL</z:chebi>) </plain></SENT>
<SENT sid="5" pm="."><plain>Several mechanisms are likely to contribute to the <z:hpo ids='HP_0004943'>accelerated atherosclerosis</z:hpo> and increased <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> risk seen in type 2 diabetics </plain></SENT>
<SENT sid="6" pm="."><plain>Of these, <z:hpo ids='HP_0011998'>postprandial hyperglycemia</z:hpo>/<z:mp ids='MP_0001548'>lipemia</z:mp>, <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and <z:mp ids='MP_0001845'>inflammation</z:mp> may be the most important and under controlled contributing factors to <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The goal of this thematic issue is to address limitations of current therapies and review emerging research and therapeutic approaches that target <z:mp ids='MP_0001845'>inflammation</z:mp>, <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and other pathological mechanisms that contribute to <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> in <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>